Parkman Healthcare Partners LLC Takes $5.43 Million Position in Doximity, Inc. $DOCS

Parkman Healthcare Partners LLC acquired a new stake in shares of Doximity, Inc. (NASDAQ:DOCS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 93,500 shares of the company’s stock, valued at approximately $5,426,000. Parkman Healthcare Partners LLC owned 0.05% of Doximity as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Doximity by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company’s stock valued at $707,646,000 after buying an additional 990,923 shares during the period. Invesco Ltd. boosted its position in Doximity by 54.8% during the 1st quarter. Invesco Ltd. now owns 1,969,326 shares of the company’s stock worth $114,280,000 after purchasing an additional 696,923 shares during the period. Fuller & Thaler Asset Management Inc. boosted its position in Doximity by 9.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company’s stock worth $100,408,000 after purchasing an additional 150,574 shares during the period. Bank of New York Mellon Corp boosted its position in Doximity by 8.2% during the 1st quarter. Bank of New York Mellon Corp now owns 1,137,912 shares of the company’s stock worth $66,033,000 after purchasing an additional 86,135 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Doximity during the 1st quarter worth $65,702,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on DOCS shares. Bank of America upped their price target on shares of Doximity from $55.00 to $62.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 25th. Piper Sandler upped their price target on shares of Doximity from $65.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. The Goldman Sachs Group set a $50.00 price target on shares of Doximity and gave the stock a “neutral” rating in a research report on Wednesday, May 21st. KeyCorp upped their price target on shares of Doximity from $65.00 to $70.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Finally, Wells Fargo & Company upped their price target on shares of Doximity from $55.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Doximity presently has an average rating of “Moderate Buy” and a consensus target price of $66.21.

Doximity Price Performance

Shares of DOCS stock opened at $69.31 on Friday. Doximity, Inc. has a 12 month low of $35.32 and a 12 month high of $85.21. The firm has a market capitalization of $12.98 billion, a P/E ratio of 69.31, a P/E/G ratio of 4.10 and a beta of 1.37. The company’s fifty day moving average price is $62.66 and its two-hundred day moving average price is $60.05.

Doximity (NASDAQ:DOCS) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same period last year, the company posted $0.28 EPS. Doximity’s revenue for the quarter was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, sell-side analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current year.

Insiders Place Their Bets

In other news, Director Regina M. Benjamin sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director owned 16,618 shares in the company, valued at approximately $997,080. This represents a 37.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Timothy S. Cabral sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the sale, the director owned 6,360 shares in the company, valued at approximately $381,600. This trade represents a 61.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,000 shares of company stock worth $1,929,380 in the last quarter. 31.30% of the stock is owned by corporate insiders.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.